Companies › Rigerna Therapeutics Co., Ltd.; Rigerna Therapeutics (Beijing)
1 active drug program in 3 registered trials: 2 Phase 1, 1 Phase 2; Genitourinary, Other; next expected readout Dec 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| RG002C0106 siRNA targeting complement C3 to silence the gene and inhibit C3 protein expression | C3 | Phase 2 | IgA Nephropathy (IgAN); Safety Issues; Renal Impairments | Dec 2026 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06494527 | RG002C0106 | Phase 1 | Safety Issues | Other | Aug 2026 |
| NCT07445906 | RG002C0106 | Phase 1 | Renal Impairments | Genitourinary | Dec 2026 |
| NCT07305974 | RG002C0106 | Phase 2 | IgA Nephropathy (IgAN) | Genitourinary | Mar 2029 |
Apellis Pharmaceuticals Annexon Kodiak Sciences Shenyang Sunshine Pharmaceutical Swedish Orphan Biovitrum
Apellis Pharmaceuticals Shanghai Bao Pharmaceuticals Akebia Therapeutics Healx Skingenix
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.